Results of 10 years of the Colorectal Cancer Prevention Program in the Valencian Community
e202107100
Keywords:
Colorectal cancer, Cancer screening, Early cancer detection, National health programsAbstract
Background: The population-based Program for the Prevention of Colorectal Cancer (PPCRC) was implemented in 2005 in the Valencian Community, following the guidelines of the European Union. To achieve the desired effectiveness in these programs, it is necessary to achieve a series of requirements, assessable through the program indicators. The objective of this study was to analyze the evolution of the program indicators from 2006 to 2016.
Methods: The accumulated indicators for the period were calculated. The Poisson regression model was used to compare the indicators by age groups and sex, by type of screening, by type of fecal occult blood test (FOBT) and by year.
Results: The number of people invited to participate was 1,934,266. The participation rate was 44.4%, being 87.6% in the subsequent screening and 33.7% in the initial one, with men over 60 having the lowest participation figures. Except for the positive predictive value (PPV) for low risk adenomas, which was higher in a group of men aged 50 to 59 years of successive screening, the detection rates and PPV for the different types of lesions were higher in the initial screening, with immunological test and in the group of men over 60 years old. Throughout the period, there was a decrease in the test positivity rates and in the advanced adenomas and cancers detection rates.
Conclusions: The PPCCR reaches levels of quality for which the effectiveness of the program is demonstrated. However, the insufficient participation of some population groups highlights the need to carry out studies to achieve the desired objectives in all population groups and thus result in greater effectiveness of the program.
Downloads
References
Council of the European Union. Council recommendation of 2 December 2003 of cancer screening (2003/873/EC). Off.J.Union 327,34-38; 2003.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
Conselleria de Sanitat Universal i Salut Pública. Estrategia contra el cáncer de la Comunitat Valenciana 2019-2022. 2019.
Segnan N, Patnick J, Von Karsa L, editors. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edit. Luxemburg; 2010.
Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015 May;64(5):784–90.
Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane database Syst Rev. 2007 Jan;2007(1):CD001216.
García Martínez M, Binefa Rodríguez G, Milà Díaz N, Rodríguez Moranta F, Gonzalo Diego N, Muñoz Sánchez C et al. [Evaluating colorectal cancer screening strategies (immunological test vs biochemical test) in Catalonia, Spain 2008-2010]. Rev Esp Salud Publica. 2011 Dec;85(6):593–602.
Faivre J, Dancourt V, Denis B, Dorval E, Piette C, Perrin P et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur J Cancer. 2012;48(16):2969–76.
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N et al. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Vol. 21, Annals of Oncology. 2010. 448–458 p.
Salas Trejo D, Portillo Villares I, Espinàs Piñol JA, Ibáñez Cabanell J, Vanaclocha Espí M, Pérez Riquelme F et al. Implementation of colorectal cancer screening in Spain: main results 2006-2011. Eur J cancer Prev Off J Eur Cancer Prev Organ. 2017 Jan;26(1):17–26.
Villares IP, Arana-Arri E, Rubio II, Piñol JAE, Riquelme FP, De La Vega Prieto M et al. Lesiones detectadas en seis programas poblacionales de cribado de cáncer colorrectal en españa. Proyecto cribea. Rev Esp Salud Publica. 2017;91:1–10.
van der Vlugt M, Grobbee EJ, Bossuyt PM, Bongers E, Spijker W, Kuipers EJ et al. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br J Cancer. 2017 Jan;116(1):44–9.
Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. World J Gastroenterol. 2017 May;23(20):3632–42.
Solé Llop ME, Cano del Pozo M, García Montero J-I, Carrera-Lasfuentes P, Lanas Á. Programa de cribado poblacional de cáncer colorrectal en Aragón. Primeros resultados. Gac Sanit. 2018;32(6):559–62.
Brugos-Llamazares V, De Aledo Linos ÁG, Vada-Sánchez J, Terán-Lantarón Á. Resultados del programa de detección precoz de cá ncercolorrectal en cantabria durante el periodo noviembrede 2008 a marzo de 2010. Rev Esp Salud Publica. 2010;84(6):757–70.
Kapidzic A, van der Meulen MP, Hol L, van Roon AHC, Looman CWN, Lansdorp-Vogelaar I et al. Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia. Clin Gastroenterol Hepatol. 2015 Aug 1;13(8):1464-1471.e4.
Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015 Aug;64(8):1327–37.
Málaga López A, Salas Trejo D, Sala Felis T, Ponce Romero M, Goicoechea Sáez M, Andrés Martínez M et al. [Programme of screening for colorrectal cancer in the Valencia community, Spain: results of the first round (2005-2008)]. Rev Esp Salud Publica. 2010;84(6):731–43
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 María Besó Delgado, Josefa Ibáñez Cabanell, Elena Pérez Sanz, Mª José Valverde Roig, Carmen Fernández García, Mercedes Vanaclocha Espí, Ana Molina-Barceló, Dolores Salas Trejo, Grupo de Trabajo del Programa de Prevención de Cáncer Colorrectal de la Comunitat Valenciana
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
